Search results | orphan

Reports

Partnering Agreements with Swedish Orphan Biovitrum

The Partnering Agreements with Swedish Orphan Biovitrum report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

Orphan Diseases Partnering Terms and Agreements

The Orphan Diseases Partnering Terms and Agreements report provides an understanding and access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in orphan diseases partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Orphan diseases partnering contract documents Top orphan diseases deals more »

Insights

Orphan diseases partnering: A lucrative step for drug makers

By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.

Swedish Orphan Biovitrum: Partnering activity 2009-2014

Swedish Orphan Biovitrum, a specialty biopharmaceutical company is dedicated to improving lives of rare diseases patients. Sobi is known for its continuous innovation in its product pipeline giving it a top position in the biotech market.

Swedish Orphan Biovitrum; Partnering its own and others rare disease products

Swedish Orphan Biovitrum is a biopharmaceutical company developing therapies and services for rare diseases and their patients around the world.

Orphan drug

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical…

Orphan drug status

A classification granted in the U.S. or the E.U.

Orphan Diseases: recent partnering deal trends

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.

Swedish Orphan Biovitrum: Company Profile

Swedish Orphan Biovitrum, a top big biotech company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years.

Dealmakers weekly review – February 20 2012 – Biogen Idec, Stromedix, Tetraphase, BioGaia, Nexmed, Swedish Orphan Biovitrum

Partnering was up on the previous week in terms of number of deals, but no deals of financial significance were announced. Partnering in terms of big headline deals seems to have taken breather for the past few weeks.

Blog matters: What to do with Orphan IP?

Source: Duncan Bucknell, IP Thinktank “Orphan IP” is intellectual property which has not been commercialised. Usually relating to patents and know-how (confidential information) in the technology transfer area, it has been the subject of many and varied ‘revolutionary’ suggestions.

Roche drops business merger rumors with Chugai Pharmaceutical

Roche had business merger rumors to buy Tokyo-based Chugai Pharmaceutical Co., Ltd. appear to be tabled for now. Sources in Roche indicated the company was focused on its $8.3 billion acquisition of California-based InterMune Inc.

Events

Sorry, your search returned no results.


Deals

X-chem and Pfizer sign a pharma deal for orphan diseases

X-Chem announced a multi-target pharma deal with Pfizer.

Swedish Orphan Biovitrum biotech partners Auxilium Pharmaceuticals

Auxilium biotech partners Swedish Orphan Biovitrum in long-term collaboration for development, supply and commercialization of XIAPEX.

Big pharma Biogen Idec partners on clinical trials with Swedish Orphan Biovitrium

Biogen Idec, a top big pharma company and Swedish Orphan Biovitrum announced the initiation of two global pediatric clinical trials of the companies’ long-lasting recombinant Factor VIII and Factor IX Fc fusion proteins in hemophilia A and B.

Shire nabs Bay Area’s Ferrokin, orphan drug in $325 million buyout

Shire announces that it has signed an agreement to acquire FerroKin BioSciences for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.

Refacto AF supply agreement extended until 2020 for Swedish Orphan Biovitrum and Pfizer

Sobi and Pfizer have extended their supply agreement for ReFacto AF®/XYNTHA® until 31 December 2020, with an option to be further renewed. The previous agreement was due to expire in 2015.

Swedish Orphan Biovitrum’s co-promotion rights for Mimpara sold back to Amgen

Swedish Orphan Biovitrum has announced a mutual agreement with Amgen whereby Swedish Orphan Biovitrum will sell back its co-promotion rights in the Nordic countries for Mimpara® (cinacalcet) to Amgen for strategic business reasons. Swedish Orphan Biovitrum will receive an undisclosed payment from Amgen for these rights upfront.

Swedish Orphan Biovitrum extends Cyanokit cooperation with Merck Serono

Under the agreement the distribution territories will include Ireland, UK and The Netherlands in addition to the existing territories the Nordic and the Baltic countries.

Swedish Orphan Biovitrum agrees to additional Kineret drug campaign with Amgen

Under the agreement Amgen will run an additional Kineret® campaign at its Boulder facility in Colorado, as well as manufacture drug product at its facility in Puerto Rico.

BioXcel and Takeda in repurposing pact for rare diseases

BioXcel has entered into a partnership with Takeda Development Center Americas for the repurposing of assets across the gamut of rare diseases

AstraZeneca and Orca Pharma in ROR gamma inhibitor pact

Orca Pharmaceuticals and AstraZeneca announced a three year collaboration to develop inhibitors of retinoic acid–related orphan nuclear receptor gamma